glp 1 oral drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog The European Medicines Agency has
Description
Gerich, J
Oral administration of corn zein hydrolysate stimulates GLP-1 and GIP secretion and improves glucose tolerance in male normal rats and Goto-Kakizaki rats
However the number of subjects that experienced adverse effects leading to study discontinuation were approximately 5x and 20x higher than that of liraglutide, respectively
Novo Nordisk has already filed Wegovy for heart failure with preserved ejection fraction, a condition that is substantially driven by hypertension and obesity and Ozempic has been filed for peripheral artery disease (Prime Therapeutics, 2025)
Canada The Canadian government has not directed clinicians to reserve GLP-1 agonists for certain patients
In conclusion, GLP-1 agonists are a promising treatment option for weight loss in PCOS patients
